Using Polyacrylamide Hydrogels to Model Physiological Aortic Stiffness Reveals that Microtubules Are Critical Regulators of Isolated Smooth Muscle Cell Morphology and Contractility

Sultan Ahmed†, Robert. T. Johnson*, Reesha Solanki, Teclino Afewerki, Finn Wostear and Derek. T. Warren

School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, United Kingdom

INTRODUCTION

Vascular smooth muscle cells (VSMCs) are the predominant cell type in the medial layer of the arterial wall. VSMCs normally exist in a quiescent, contractile phenotype where actomyosin-derived contractile forces maintain vascular tone (Brozovich et al., 2016). However, VSMCs are not terminally differentiated and can dedifferentiate into a proliferative, synthetic phenotype. Actomyosin force generation is essential for the function of both phenotypes. Whilst much is already known about the mechanisms of VSMC actomyosin force generation, existing assays are either low throughput and time consuming, or qualitative and inconsistent. In this study, we use polyacrylamide hydrogels, tuned to mimic the physiological stiffness of the aortic wall, in a VSMC contractility assay. Isolated VSMC area decreases following stimulation with the contractile agonists angiotensin II or carbachol. Importantly, the angiotensin II induced reduction in cell area correlated with increased traction stress generation. Inhibition of actomyosin activity using blebbistatin or Y-27632 prevented angiotensin II mediated changes in VSMC morphology, suggesting that changes in VSMC contractility are core components of the contractile response. Furthermore, we show that microtubule stability is an essential regulator of isolated VSMC contractility. Treatment with either colchicine or paclitaxel uncoupled the morphological and/or traction stress responses of angiotensin II stimulated VSMCs. Our findings support the tensegrity model of cellular mechanics and we demonstrate that microtubules act to balance actomyosin-derived traction stress generation and regulate the morphological responses of VSMCs.

Keywords: actomyosin, contraction, matrix stiffness, microtubules, polyacrylamide hydrogel (PAH), traction force, vascular smooth muscle cell (VSMC)
phenotypes retain the ability to generate actomyosin force that is essential for both VSMC contraction and migration (Ahmed and Warren, 2018; Afewerki et al., 2019). Contractile VSMCs possess a greater abundance of α-smooth muscle actin (αSMA) and smooth muscle-myosin heavy chain (SM-MyHC), that enhance their ability to generate actomyosin forces and contract (Rensen et al., 2007). However, both contractile and proliferative VSMCs generate actomyosin force via stimulating interactions between myosin II and filamentous actin. This process is regulated in both phenotypes by blood-borne factors, such as angiotensin II, that bind to receptors on the VSMC surface and mechanical factors including matrix stiffness and circumferential tension of the aortic wall (Qiu et al., 2010; Brozovich et al., 2016; Ahmed and Warren, 2018).

Young’s modulus is a measure of material stiffness. Atomic force microscopy studies have determined that the Young’s modulus of the medial layer of an elastic artery is between 5 and 37 kPa (Tracqui et al., 2011; Bae et al., 2016; Rezvani-Sharif et al., 2019). Microenvironment rigidity transmits ‘outside-in’ resistive forces to VSMCs and this process is dependent on focal adhesions that convey force between the extracellular matrix (ECM) and the cytoskeleton (Lacolley et al., 2017; Ahmed and Warren, 2018; Mohammed et al., 2019). VSMCs and other cell types respond to outside-in signals by exerting actomyosin based contractile forces on the matrix (inside-out forces) that scale with the outside-in resistive forces (Sun et al., 2008; Holle et al., 2018). Matrix rigidity rapidly activates Rho/ROCK signalling at ECM adhesions, initiating actin polymerisation and myosin light chain phosphorylation, thereby augmenting actomyosin activity (Ahmed and Warren, 2018). Actin cytoskeletal reorganisation and enhanced actomyosin activity increase VSMC integrated traction forces, the force VSMCs apply to the ECM (Li et al., 2020; Johnson et al., 2021). While much is known about VSMC actomyosin and contractile responses, we still lack an understanding of how VSMC structural and signalling components integrate to regulate these processes.

Extracellular mechanical forces, generated by the flow of blood and the mechanical properties of the ECM, programme the function of VSMCs (Johnson et al., 2021). In healthy arteries, VSMC contraction is initiated in response to blood pressure derived deformation of the arterial wall (Ye et al., 2014). However, these forces are not consistent and physiological cycle-by-cycle variations in blood pressure have been found to alter the contractile response of VSMCs (Bartolák-Suki et al., 2015; Bartolák-Suki and Suki, 2020). During ageing, the mechanical environment changes. Blood pressure increases, enhancing the compressional forces applied to the arterial wall; whilst the tensile strength and rigidity of the wall increases due to ECM remodelling (Tsamis et al., 2013). In response to these altered mechanical cues, VSMCs generate enhanced actomyosin derived contractile forces (Ye et al., 2014). This results in arterial stiffening, a hallmark of vascular ageing and cardiovascular disease onset (Glasser et al., 1997; Mitchell et al., 2010). How matrix stiffness induces enhanced VSMC actomyosin force production is unknown, but it is a response that is observed in many other cell types (Discher et al., 2005; Zhou et al., 2017; Pasqualini et al., 2018; Bastounis et al., 2019). It is therefore imperative that studies investigating VSMC physiological force generation take this mechanical property into account. Traditionally, many in vitro experiments have cultured isolated VSMCs on plastic or glass, materials whose stiffness is around a thousand times greater than that of the arterial wall (Minaisah et al., 2016). More recently, the role of matrix stiffness in regulating VSMCs has been investigated using polyacrylamide hydrogels, a substrate whose stiffness can be tuned to a desired kPa. These studies have identified that matrix stiffness is a regulator of VSMC phenotype, with enhanced stiffness altering the proliferative, migratory and adhesive properties of VSMCs (Wong et al., 2003; Xie et al., 2018; Nagayama and Nishimiya, 2020; Rickel et al., 2020). Furthermore, matrix rigidity promoted actin cytoskeleton remodelling and stress fiber formation, increasing VSMC stiffness and traction stress generation (Brown et al., 2010; Sazonova et al., 2015; Petit et al., 2019; Sanyour et al., 2019). Whilst these studies controlled ECM rigidity, many of them made use of high passage VSMCs and culture conditions that would promote the synthetic phenotype. Therefore, the findings have little relevance for understanding VSMC contractile function.

Actomyosin derived contractile forces place stress and intracellular tension upon the cell. In other cell types, these deformational forces are proposed to be balanced by the ECM and the microtubule network (Johnson et al., 2021). This relationship is described by the tensegrity model, whereby microtubules act as compression bearing struts, capable of resisting strain generated by the actin cytoskeleton (Stamenović, 2005; Brangwynne et al., 2006). The balance between compression and strain defines cell shape and stability (Stamenović, 2005). This model predicts that microtubule destabilisation will increase actomyosin derived force generation. In support of this, treatment with microtubule destabilisers, such as colchicine, result in enhanced force generation within coronary and aortic vessels (Sheridan et al., 1996; Platts et al., 1999, 2002; Paul et al., 2000; Zhang et al., 2000). However, our understanding of the role of microtubules in VSMC contractile agonist responses remains limited and some data contradicts the tensegrity model. For example, wire myography showed that microtubule stabilisation had no effect on the ability of isolated aortic rings to contract (Zhang et al., 2000). Dynamic instability, the ability of microtubules to constantly cycle through phases of growth and shrinkage, is an inherent characteristic that enables the microtubule network to rapidly reorganise in response to the changing mechanical requirements of the cell (Nogales, 2001). Whilst observations regarding the function of microtubule stability in VSMC contraction have been made, our understanding of the mechanisms behind these observations remains incomplete.

One of the largest obstacles for identifying different mechanisms of VSMC contraction remains the lack of in vitro tools. The current gold standard for assessing isolated cell actomyosin activity is traction force microscopy (TFM) (Muhamed et al., 2017). TFM is used to quantitatively measure the stress exerted by a cell on its substrate, which is then used as an indicator of cell contractility (Kraning-Rush et al.,...
Vascular Smooth Muscle Cell Culture and Drug Treatments

Human adult aortic VSMCs (passage 3–10) were purchased from Cell Applications Inc. (354-05a). VSMCs were grown in growth media (Cell Applications Inc.), prior to being washed with Earle’s Balanced Salt Solution (Thermo) and seeded in basal media (Cell Applications Inc.) onto 12 kPa hydrogels, 18 h prior to drug treatment. Standard VSMCs culture was performed as described previously (Ragnauth et al., 2010; Warren et al., 2015).

Quiescent VSMCs were stimulated with either angiotensin II (0.01–100 µM) (Merck) or carbachol (0.01–100 µM) (Merck) for 30 min. For all other drug treatments, quiescent VSMCs were pretreated with the stated dose for 30 min, prior to co-treatment with angiotensin II (10 µM) for an additional 30 min. Please see Supplementary Table S1 for a list of compounds used in this study.

Immunofluorescence and VSMC Area/Volume Analysis

Following treatment, cells were fixed in 4% paraformaldehyde (actin cytoskeleton) or ice-cold methanol (microtubules), permeabilised with 0.5% NP40 and blocked in 3% BSA/PBS. Targets were visualized using antibodies raised against lamin A/C (SAB4200236, Sigma), or α-tubulin (3873S, CST) in combination with a relevant Alexa Fluor 488 secondary antibody (A1101 or A1103, Thermo). F-actin was stained using Rhodamine Phalloidin (R145, Thermo). All images were captured at 20x (cell area/volume) or 40x (microtubule organization) magnification using either a Zeiss LSM510-META or a Zeiss LSM980-Airyscan confocal microscope. Cell area was measured using Fiji, open-source software (Schindelin et al., 2012), whilst cell volume was calculated using Velocity 6.3.

Cold-Stable Microtubule Stability Assay

The number of cold-stable microtubules per cell was determined as previously (Atkinson et al., 2018). Briefly, after treatment, cells were placed on ice for 15 min before being washed once with PBS and twice with PEM buffer (80 µM PIPES pH 6.8, 1 mM EGTA, 1 mM MgCl₂, 0.5% Triton X-100 and 25% (w/v) glycerol) for 5 min. Cells were then fixed for 20 min in ice-cold MeOH and prepared for staining as detailed above. Cell nuclei were identified using DAPI. Images were captured at 40x magnification using an Axioplan Epifluorescent microscope.

Traction Force Microscopy

For Traction Force Microscopy (TFM), VSMCs were seeded onto 12 kPa hydrogels containing 0.5 µm red fluorescent (580/605) FluoSpheres (1:100) (Invitrogen). Imaging was performed using a Zeiss Axio Observer live cell imaging system that captured 20x magnification images every 2 min. TFM was performed either in real-time or as an end point assay whereby images were captured before and after cell lysis. Lysis was achieved by the addition of 0.5% Triton X-100. Drift was corrected using the ImageJ StackReg plugin and traction force was calculated using the ImageJ plugin described previously to measure FluoSphere displacement (Tseng et al., 2012; Lekka et al., 2021). Additionally, atomic force microscopy (AFM) has been used to assess actomyosin cortical tension and the force transduced through individual focal adhesion complexes (Sanyour et al., 2019). However, these techniques have several limitations, mainly being time consuming and low throughput (Haase and Pelling, 2015; Colin-York and Fritzschke, 2018; Schierbaum et al., 2019). Collagen gel assays, that are easily fabricated and mimic the rigidity of the physiological arterial wall (Minaisah et al., 2016; Porter et al., 2020).

Polyacrylamide Hydrogel Preparation

Hydrogels were prepared as described previously (Minaisah et al., 2016). Briefly 30 mm coverslips were activated by treating with (3-Aminopropyl)triethoxysilane for 2 min, washed 3x in dH₂O and fixed in 0.5% glutaraldehyde for 40 min. Coverslips were subsequently washed 3x in dH₂O and left to air dry. The required volume of 12 kPa polyacrylamide hydrogel mix (7.5% acrylamide, 0.15% bis-acrylamide in water) was supplemented with 10% APS (1:100) and TEMED (1:1000) before 50 µl of the solution was placed on a standard microscopy slide and covered by an activated coverslip. Once set, the fabricated 12 kPa hydrogel was removed, placed into a 6-well plate, washed 3x with dH₂O and crosslinked with sulfo-SANPAH (1:3,000) under UV illumination (365 nm). Finally, hydrogels were washed with PBS and functionalised with collagen I (0.1 mg/ml) for 10 min at room temperature. Hydrogel stiffness was previously confirmed using a JPK Nanowizard-3 atomic force microscope (Porter et al., 2020).

MATERIALS AND METHODS
FIGURE 1 | VSMCs grown on pliable hydrogels display decreased area upon stimulation with the contractile agonist angiotensin II. (A) Representative images of isolated VSMCs cultured on 12 kPa polyacrylamide hydrogels treated with a range of angiotensin II concentrations for 30 min. Actin cytoskeleton (purple) and Lamin A/C labelled nuclei (green). Scale bar = 100 μm. (B) Isolated VSMC area, representative of 3 independent experiments with ≥150 cells analysed per condition. (C) EC₅₀ of angiotensin II calculated from (B). (D) Representative images of isolated VSMCs cultured on 12 kPa hydrogels and treated with angiotensin II (10 μM) for 30 min in the presence of a range of irbesartan concentrations. Actin cytoskeleton (purple) and Lamin A/C (green). Scale bar = 100 μm. (E) Isolated VSMC area, representative of 3 independent experiments with ≥50 cells analysed per condition. (F) IC₅₀ of irbesartan calculated from (E). (** = p < 0.01), (*** = p < 0.001).
et al., 2012). Briefly, bead displacement was measured using the first and last image of the movie sequence. The cell region was segmented by overlaying the traction map with the cell image, highlighting the cell traction region with an ROI and extracting the traction forces in each pixel by using the save XY coordinate function in FIJI (Porter et al., 2020).

Cell Viability Assay

Cell viability was determined using a RealTime-Glo™ MT Cell Viability Assay following manufacturers instruction. Briefly, 5,000 cells per well in a 96-well plate were exposed to a range of drug concentrations for 1 h, prior to luminescence being measured using a Wallac EnVision 2,103 Multilabel Reader (PerkinElmer).

Statistics

All statistical analyses were performed in GraphPad Prism 6.05. Dose response curves are presented as the mean data ± SEM (error bars) plotted on a logarithmic dose response scale. EC50 and IC50 data were generated by non-linear regression. Results are presented as mean ± SEM. Dot plot graphs are presented to show data distribution, with each point corresponding to an individual cell measurement. Bars indicate the mean value, ± SEM (error bars). Comparison of multiple groups was achieved using one-way ANOVA analysis with Bonferroni post-hoc test. For comparison of two groups, unpaired student t-tests were performed. Analysis of the real time Angiotensin II contraction data was performed using non-linear regression. A one phase association analysis was performed on traction stress vs time data and a one phase decay analysis was performed on the VSMC area vs time data.

RESULTS

Contractile Agonist Stimulation Reduces VSMC Area on Pliable Hydrogels

We set out to develop a screen, performed at a physiologically relevant rigidity, to unravel mechanisms regulating VSMC actomyosin activity and contraction (Supplementary Figure S1). Quiescent VSMCs grown on pliable, 12 kPa hydrogels were treated with a concentration range of the contractile agonists, angiotensin II or carbachol. Contractile response was measured through changes in VSMC area, which previous studies have shown correlates with isolated VSMC contractile activity (Li et al., 1999; Wang et al., 2017; Halaidych et al., 2019). Analysis confirmed that contractile agonist stimulation resulted in a reduction in VSMC area (Figures 1A,B and Supplementary Figures S2A,B). Further analysis of VSMC area revealed the assay could be used to determine the EC50 values of both angiotensin II and carbachol (Figure 1C and Supplementary Figures S2C), confirming the assay could be used to measure and compare agonist potency. Subsequent experiments were performed with 10 µM angiotensin II, a dose that produced the maximal response (Figures 1A,B). To observe the effect of angiotensin II stimulation on isolated VSMC volume, we next performed confocal microscopy. Analysis revealed that angiotensin II stimulated VSMCs displayed a reduction in area, but no change in volume (Supplementary Figure S3).

To confirm that the change in area was specific for receptor activation, we utilised the angiotensin II antagonist irbesartan and the cholinergic antagonist, atropine. VSMCs grown on pliable hydrogels were stimulated with angiotensin II or carbachol in the presence of an increasing dose of irbesartan or atropine, respectively. As expected, irbesartan and atropine treatment prevented a reduction in VSMC area, confirming that these changes were driven by receptor activation (Figures 1D–F and Supplementary Figure S4).

Myosin II Mediated Traction Stress Drives Changes in Angiotensin II Stimulated VSMC Area

The above data demonstrated the validity of our approach in generating EC50 and IC50 data for agonists/antagonists of isolated VSMC contractile function. We next sought to confirm that changes in VSMC area were due to contraction and not due to membrane retraction. To do this, we performed traction force microscopy to measure the displacement of beads embedded within the hydrogels. Analysis revealed that angiotensin II treatment stimulated VSMCs to contract, with a significant reduction in cell area observed after 8 min (Figures 2A,B). Importantly, beads moved towards VSMCs and both maximal and integrated traction stress increased rapidly and plateaued after 8 min (Figures 2A,C,D). This data confirmed the correlation between reduced VSMC area and traction stress generation upon angiotensin II stimulation. To further confirm that actomyosin derived force was driving these changes in VSMC area, we next used the myosin II inhibitor blebbistatin and the ROCK inhibitor Y-27632. As expected, treatment with either blebbistatin or Y-27632 blocked the angiotensin II mediated reduction in area, however, actomyosin inhibited VSMCs possessed an increased volume, compared to their angiotensin II treated counterparts (Figure 3). This confirmed that actomyosin activation was driving VSMC contraction in our system.

Microtubule Destabilisation Alters the Morphological Response of Angiotensin II Stimulated VSMCs

Microtubule depolymerisation increases the constriction and myogenic tone of aortic and carotid tissues (Leite and Webb, 1998; Platts et al., 2002; Johnson et al., 2021). However, the precise impact of microtubule disruption on VSMC contraction remains unknown. To address this, we determined the impact of angiotensin II stimulated VSMC contraction upon microtubule organisation and stability. Angiotensin II stimulation promoted the microtubule network to reorganise, switching from a straight, elongated arrangement of parallel microtubules to a more interlinking meshwork of microtubules (Supplementary Figure S5). Although angiotensin II stimulation induced the reorganisation of the microtubule cytoskeleton, there was no change in the number of cold-stable microtubules between
quiescent and angiotensin II stimulated VSMCs (Figures 4A,B). Next, we used our assay to test the impact of microtubule disruption on VSMC contraction. Colchicine, a microtubule destabiliser, induced a concentration dependent increase in angiotensin II treated VSMC area, suggesting that microtubule depolymerisation was promoting VSMC relaxation (Figures 4C–E). In contrast, paclitaxel, a microtubule stabiliser, had no effect on the area of angiotensin II treated VSMCs (Figures 4F,G). Analysis confirmed that the concentrations of colchicine or paclitaxel used were sufficient to reduce or increase the number of cold-stable microtubules respectively (Supplementary Figures S6A–D). Furthermore, these concentrations produced no
significant reductions in cell viability (Supplementary Figures S6E,F). Surprisingly, confocal microscopy revealed that colchicine increased VSMC volume (Figures 5A–C), whereas the volume of paclitaxel treated VSMCs remained unchanged (Figure 5D–F).

Changes in Microtubule Stability Alters the Traction Stress Generation of Isolated VSMCs
The data above suggested that microtubule destabilisation was altering the angiotensin II induced area/volume response of isolated VSMCs. Previous studies using wire or pressure myography have reported that microtubule destabilisation increased VSMC force generation (Paul et al., 2000; Zhang et al., 2000; Platts et al., 2002). To confirm the impact of microtubule destabilisation on actomyosin activity, TFM was performed to measure traction stresses exerted by VSMCs. In agreement with previous studies, analysis revealed that pretreatment with colchicine increased the maximal and total traction stress exerted by angiotensin II stimulated VSMCs (Figures 6A–C). Finally, we examined the effect of microtubule stabilisation on traction stress. Paclitaxel pre-treatment had no effect on maximal traction stress. However, total traction stress was reduced when compared to their untreated counterparts (Figures 6D–F). This confirmed that maintenance of microtubule dynamics was essential for VSMC actomyosin activity and force generation.

DISCUSSION
Whilst much is known about VSMC contractile responses in physiology, in vitro assays to examine this process remain limited. Tissue culture plastic and glass are approximately a thousand times stiffer than the aortic wall (Minaisah et al., 2016), meaning that changes in VSMC area are driven by membrane retraction rather than contraction. Existing technologies to examine the contractile response of isolated VSMCs are either low throughput, such as TFM, or are
FIGURE 4 | Microtubule destabilisation prevents angiotensin II induced changes in VSMC area. (A) Representative images of isolated VSMCs cultured on 12 kPa polyacrylamide hydrogels, stained for cold-stable microtubules (α-tubulin, red) and cell nuclei (DAPI, blue). Scale bar = 50 µm. Angiotensin II (AngII) (10 µM) stimulation was performed for 30 min. (B) Number of cold-stable microtubules per cell, representative of 4 independent experiments, with ≥90 cells analysed per condition. (C) Representative images of isolated VSMCs cultured on 12 kPa hydrogels pre-treated with a range of colchicine concentrations for 30 min prior to cotreatment with angiotensin II (10 µM) for an additional 30 min. Actin cytoskeleton (purple) and Lamin A/C (green). Scale bar = 100 µm. (D) Isolated VSMC area, representative of 3
inconsistent and lack rigidity control, such as the collagen gel assay (Vernon and Gooden, 2002; Colin-York and Fritzsch, 2018). We therefore set out to establish and validate a polyacrylamide hydrogel-based assay for screening the contractility of isolated VSMCs. Polyacrylamide hydrogels are widely used in cell biology and can be easily fabricated with generic research equipment and skills (Kandow et al., 2007; Caliari and Burdick, 2016; Minaisah et al., 2016; Mohammed et al., 2019). To enable VSMC attachment,
polyacrylamide hydrogels mimicking physiological rigidity must be functionalised by ECM components such as collagen, fibronectin or lamin (Brown et al., 2010; Sazonova et al., 2015). Previous studies have utilised hydrogels of varying stiffness to identify matrix rigidity as a key regulator of VSMC morphology, migration, proliferation and phenotype. In response to matrix stiffness, VSMCs downregulate the expression of contractile markers SM-MyHC, calponin and smoothelin, whilst increasing the expression of proliferative genes Cyclin A and PCNA (proliferating cell nuclear antigen), in correlation with increased VSMC proliferation (Brown et al., 2010; Sazonova et al., 2015; Xie et al., 2018; Nagayama and Nishimiya, 2020). Additionally, VSMCs undergo durotaxis, preferentially migrating from soft to stiff matrix rigidity, although the effect of matrix stiffness on the rate of migration appears dependent on the ECM component (Wong et al., 2003; Rickel et al., 2020).

In our present study, we describe a novel assay in which agonist induced VSMC contraction is performed on a substrate of physiological stiffness. We demonstrate that changes in isolated VSMC area were driven by angiotensin II induced traction stress generation, that pulled the compliant hydrogels towards the VSMC, decreasing cell area (Figures 1A, B, 2). Demonstrating that isolated VSMC area can be used as a reporter of contractility on pliable hydrogels. VSMC volume remained unchanged by

**FIGURE 6** | Microtubule stability regulates angiotensin II induced VSMC traction stress generation. (A) Representative phase images and bead displacement heat maps of isolated VSMCs grown on 12 kPa polyacrylamide hydrogels. Cells were pre-treated +/− colchicine (100 nM) for 30 min prior to cotreatment with angiotensin II (AngII) (10 µM) for an additional 30 min. Scale bar = 100 µm. (B) Maximum traction stress and (C) Total traction stress generation. Both (B,C) are representative of 3 independent experiments with ≥48 cell analysed per condition. (D) Representative phase images and bead displacement heat maps of isolated VSMCs grown on 12 kPa polyacrylamide hydrogels. Cells were pre-treated +/− paclitaxel (1 nM) for 30 min prior to cotreatment with angiotensin II (AngII) (10 µM) for an additional 30 min. Scale bar = 100 µm. (E) Maximum traction stress generation and (F) Total traction stress generation. Both (E,F) are representative of 3 independent experiments with ≥38 cell analysed per condition. (n.s. = non-significant), (" = p < 0.01), (** = p < 0.001), (**** = p < 0.0001).
contractile agonist stimulation (Supplementary Figure S3). Importantly, this assay was sensitive enough to generate EC50 and IC50 information of contractile agonists and antagonists, respectively (Figures 1C,F; Supplementary Figures S2C, S4C). Whilst TFM alone can measure the contractile response of VSMCs, it requires a large number of individual cells to be analysed in order to achieve consistent results (Petit et al., 2019). Through using cell area as a marker of VSMC contractility, a concentration range of potential agonists/antagonists can be rapidly trialed, identifying the efficacy and optimal dose of a compound. Changes in VSMC area can subsequently be correlated to altered traction force generation using TFM in a targeted approach. We also predict that our assay could easily be used in conjunction with siRNA mediated depletion or overexpression strategies. Immunofluorescent staining, using antibodies against the targeted protein, would ensure only depleted or overexpressing cells are analysed. Therefore, this assay possesses the flexibility to enable the precise interrogation of complex biological pathways that regulate VSMC contractile function.

We have used this polyacrylamide hydrogel-based assay to investigate the role of microtubule stability in isolated VSMC morphology and traction stress generation. We identify microtubule stability as a critical regulator of isolated VSMC contractility and show that proper microtubule stability is essential to couple VSMC morphology and traction stress generation (Figures 4C–G, 6). Our findings fit the tensegrity model of cellular mechanics (Stamenović, 2005); microtubule destabilisation increased traction stress generation, whereas microtubule stabilisation had the opposite effect (Figure 6). Our findings are supported by previous studies that show microtubule destabilising agents promoted an increase in isometric force generation by wire myography (Sheridan et al., 1996; Platts et al., 1999, 2002; Paul et al., 2000; Zhang et al., 2000). Whilst overall microtubule stability is maintained (Figures 4A,B), angiotensin II induced contraction initiates remodelling of the microtubule network (Supplementary Figure S5). Further work is required to understand the importance of this reorganisation, however, a recent study has demonstrated that stretched-induced reorganisation of VSMC microtubules enhances the efficiency of mitochondrial ATP production, thereby increasing actomyosin force generation (Bartolák-Suki et al., 2015).

However, contradictory to our findings (Figures 6D–F), previous studies have shown that microtubule destabilisation does not alter VSMC force generation by wire myography (Zhang et al., 2000). In this study, we show that paclitaxel had no effect on VSMC morphology (Figures 4F,G) and this may potentially account for this discrepancy. Additionally, we identify the IC50 of colchicine to be within the nanomolar range (Figures 4C–E). Paclitaxel also demonstrated significant microtubule stabilisation when used in the nanomolar range (Supplementary Figures S6C,D). However, previous studies have used microtubule targeting agents in the tens of micromolar range (Platts et al., 1999; Paul et al., 2000; Zhang et al., 2000). Numerous studies have shown that these agents can be cytotoxic in micromolar and, in some cell lines, nanomolar ranges (Pasquier et al., 2006; Thomopoulou et al., 2016; Atkinson et al., 2018; Abbasi et al., 2019; Čermák et al., 2020). Meanwhile, in the present study we used these agents in nanomolar ranges, which had no effect on VSMC viability (Supplementary Figures S6E,F). Surprisingly, wire myography has shown that VSMC death does not trigger a reduction in isometric force generation (Clarke et al., 2006). Previously, a tamoxifen model that induced VSMC death resulted in the loss of approximately two thirds of VSMCs. However, the remaining VSMCs generated more contractile forces, resulting in the maintenance of the overall isometric force generation (Clarke et al., 2006). This observation may account for the divergence from the tensegrity model predictions, as seen in previous studies (Zhang et al., 2000). Clearly more research is needed to clarify the role of microtubules and cell death in regulating VSMC contractility and vascular tone.

As described above, our microtubule stabilisation/destabilisation traction stress data fits the tensegrity model of cellular mechanics (Figure 6). However, we also show that microtubule destabilisation/stabilisation uncoupled the morphological response from the amount of traction stress VSMCs generated following angiotensin II stimulation (Figure 5). In our assay, isolated VSMC volume was unchanged by contractile agonist stimulation and changes in area were driven by actomyosin induced contraction (Supplementary Figures S2, S3). Microtubule destabilisation promoted increased VSMC volume (Figures 5A,C), and we propose that this increased volume is enhancing spreading in these cells. We predicted that these cells were undergoing a hypertrophic response, however more work is needed to clarify how these cells respond over a longer time course. Surprisingly, inhibition of non-muscle myosin II or ROCK also resulted in enhanced VSMC volume (Figures 3A,C). This suggests that actin and microtubule networks may mechanically cooperate to regulate VSMC volume control. Much is known about the synergistic nature of microtubules and actomyosin activity. Indeed, non-muscle myosin II has been shown to suppress microtubule growth in order to stabilise cell morphology (Sato et al., 2020), whilst microtubule acetylation has been found to regulate actomyosin-derived force generation (Joo and Yamada, 2014; Seetharaman et al., 2021). Actomyosin and microtubule cross-talk also regulates morphology during differentiation and cell migration in a variety of cell types (Akhshi et al., 2014; Wu and Bezanilla, 2018; Seetharaman and Etienne-Manneville, 2020), suggesting that communication between these mechanical networks is fundamentally important in determining VSMC morphology.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

SA, RJ, RS, TA, and FW were responsible for performing experiments and analysed data. DW analysed data. RJ and
ACKNOWLEDGMENTS
The authors would like to thank Dr. Stefan Bidula for his critical reading of this manuscript. This research was previously submitted as a preprint on the BioRxiv server (DOI: 10.1101/2021.12.14.472278).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.836710/full#supplementary-material
Wong, J. Y., Velasco, A., Rajagopalan, P., and Pham, Q. (2003). Directed Movement of Vascular Smooth Muscle Cells on Gradient-Compliant Hydrogels. Langmuir 19, 1908–1913. doi:10.1021/la026403p

Wu, S. Z., and Bezanilla, M. (2018). Actin and Microtubule Cross Talk Mediates Persistent Polarized Growth. J. Cel Biol 217, 3531–3544. doi:10.1083/jcb.201802039

Xie, S. A., Zhang, T., Wang, J., Zhao, F., Zhang, Y. P., Yao, W. J., et al. (2018). Matrix Stiffness Determines the Phenotype of Vascular Smooth Muscle Cell In Vitro and In Vivo: Role of DNA Methyltransferase 1. Biomaterials 155, 203–216. doi:10.1016/j.biomaterials.2017.11.033

Ye, G. J., Nesmith, A. P., and Parker, K. K. (2014). The Role of Mechanotransduction on Vascular Smooth Muscle Myocytes’ [corrected] Cytoskeleton and Contractile Function. Anat. Rec. (Hoboken) 297, 1758–1769. doi:10.1002/ar.22983

Zhang, D., Jin, N., Rhoades, R. A., Yancey, K. W., and Swartz, D. R. (2000). Influence of Microtubules on Vascular Smooth Muscle Contraction. J. Muscle Res. Cel Motil 21, 293–300. doi:10.1023/A:1005600118157

Zhou, D. W., Lee, T. T., Weng, S., Fu, J., and Garcia, A. J. (2017). Effects of Substrate Stiffness and Actomyosin Contractility on Coupling between Force Transmission and Vinculin-Paxillin Recruitment at Single Focal Adhesions. Mol. Biol. Cel 28, 1901–1911. doi:10.1091/mbc.e17-02-0116

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ahmed, Johnson, Solanki, Afewerki, Westgar and Warren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.